Yahoo! JAPAN

2024/5/13 -mRNA medicines fight diseases in a different way than traditional medicine by prompting your immune system to create the tools to treat or prevent disease.

1日前 -Moderna, creator of one of a handful of Covid-19 vaccines, had to act fast in the pandemic. Speeding its first and only commercial product to market ...

12時間前 -Moderna shares were down another 7.8% Wednesday morning after falling 8% Tuesday, crimping what had been the stock's best month in years.

1日前 -Shares of Moderna (MRNA) are being driven by encouraging pipeline updates and plans for potential product launches.

2024/5/2 -Reports first quarter revenues of $167 million, GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and ...

2024/5/10 -Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and ...

2024/5/2 -In the first quarter of the year, Moderna reported $167 million in sales of its only product on the market, its COVID-19 vaccine called Spikevax. The company's ...

11時間前 -The Moderna Selloff Gains Steam. An Analyst Has a Few Theories Why. ... What began Tuesday as a puzzling dip in shares of the biotech Moderna accelerated into a ...

2024/5/2 -The company reiterated its full-year 2024 sales guidance of roughly $4 billion, which includes revenue from the expected launch of its RSV vaccine.